

SHORT COMMUNICATION

Diversity of SCCmec types in methicillin-resistant *Staphylococcus aureus* clinical isolates in southern Brazil

Diversidade dos tipos de SCCmec em isolados clínicos de Staphylococcus aureus resistente à meticilina no Sul do Brasil

Diversidad de tipos de SCCmec en aislados clínicos de Staphylococcus aureus resistentes a meticilina en el sur de Brasil

Adriana Medianeira Rossato,¹ Roberto Carlos Freitas Bug,¹ Keli Cristine Reiter,¹ Pedro Alves d'Azevedo.¹

¹Federal University of Health Science of Porto Alegre, Porto Alegre, Brazil.

Received: 06/01/2020

Accepted: 07/01/2020

Available online: 10/01/2020

Correspondent Author:

Adriana Medianeira Rossato

adrimfarma@yahoo.com.br

Keywords: *Staphylococcus aureus*. MRSA. SCCmec types.

Methicillin-resistant *Staphylococcus aureus* is one of the most frequent causes of community- and healthcare-associated infections¹. This resistance is conferred by the acquisition of the staphylococcal chromosomal cassette *mec* (SCCmec), carrying the *mecA* or *mecC* gene, which encodes an altered penicillin binding protein (PBP2a or PBP2'), presents low affinity for most beta-lactams.^{1,2} Until now, there are thirteen SCCmec types (I-XIII), highly diverse in their structural organization and genetic content, being widely used in MRSA molecular typing.² MRSA is considered to be healthcare-associated (HA-MRSA) if the isolates are recovered after 48 h of hospitalization and community-associated (CA-MRSA) if recovered in up to 48 h after hospital admission. Commonly, HA-MRSA are associated with invasive infections and belongs to SCCmec types I, II or III, while CA-MRSA are associated with skin and soft tissue infections and carries SCCmec type IV or V.^{3,4} Since SCCmec typing is useful to understand the epidemiology and clonal relatedness of these multiresistant strains.² The aim of this study was to determine the diversity of SCCmec types and subtypes in MRSA strains obtained from Hospital Mãe de Deus

(HMD), Hospital Moinhos de Vento (HMDV), Hospital Ernesto Dornelles (HED) and Hospital Nossa Senhora da Conceição (HNSC) in Porto Alegre, Brazil, between 2014 and 2019. This cross-sectional observational study was conducted with 217 non-repetitive MRSA clinical isolates, under Institutional Ethics Committee number 2.770.338. They were recovered from the respiratory tract (34.6%), blood (25.3%), skin and soft tissue (19.4%), bone and connective tissue (11.1%), sterile cavity liquids (5.5%) and medical devices (4.1%). The isolates were identified as *S. aureus* using conventional bacteriological methods, such as colony morphology on sheep blood agar, Gram staining, catalase activity, coagulase production and mannitol fermentation. The methicillin resistance was determined by cefoxitin disk diffusion method and polymerase chain reaction (PCR) to detect the *mecA* gene, according to Clinical and Laboratory Standard Institute (CLSI) guidelines.^{5,6} The bacterial DNA was extracted using Chelex 100 (Bio-Rad, Richmond, CA) and Proteinase K (Sigma-Aldrich, Poole, UK), and SCCmec types I-X (including subtypes IVa, IVb, IVc and IVd) was determined by multiplex-PCR as previously described,^{5,7} with some modifications (Table 1). The three multiplex-PCR contained 0.2 mM of

dNTPs, 2 mM of MgCl₂, 1 X of PCR buffer, 5 µL of primer mix, 1.5 U of Taq DNA polymerase and 1.5 µL of DNA template in a total volume of 25 µL. Amplifications were performed in a LifePro Thermal Cycler (Hangzhou Bioer Technology Co. Ltd., Hangzhou, China), and the PCR products were analyzed by electrophoresis in 2.0 % agarose gel (Sigma-Aldrich, United States), stained with ethidium bromide and observed on UV transilluminator. As PCR positive controls, NCTC 10442 (SCCmec I), N315 (SCCmec II), 85/2082 (SCCmec III), JCSC 4474 (SCCmec I Va), JCSC 2172 (SCCmec IVb), JCSC 4488 (SCCmec IVc), JCSC 4469 (SCCmec IVd), WIS (SCCmec V), HDE 288 (SCCmec VI), JCSC 6082 (SCCmec VII), JCSC 6943 (SCCmec I X) and JCSC 6945 (SCCmec X) were included and, as negative control a tube containing all components of the mixture, except template DNA was used. In relation to SCCmec typing, SCCmec type IV was the most common type, with a frequency of 57.1% (124/217), being 77 of subtype IVa (62.1%), 3 of IVb (2.4%), 42 of IVc (33.9%) and 2 of IVd (1.6%), followed by type III, with frequency of 17.1% (37/217); type I, with a frequency of 13.4% (29/217); type II, with a frequency of 9.2% (20/217) and type V, with a frequency of 1.4% (3/217). None of the isolates showed SCCmec types VI, VII and X. The distribution of SCCmec types between 2014 and 2019 is presented in figure 1. Interestingly, over the years, we observed a decrease of types I, II, and III and an increase of subtypes IVa and IVc among HA-MRSA. Epidemiological studies have demonstrated that SCCmec I, II, and III are the most common in HA-MRSA, whereas SCCmec IV and V predominate in CA-MRSA.^{3,4} The results of our analysis show that SCCmec IV and III were the most prevalence types among the HA-MRSA strains, followed by type I, II and V. These findings corroborate other studies, which presented that SCCmec IV and III were

the most common types identified among HA-MRSA isolates, in varying proportions.^{8,9} The presence of SCCmec types IV and V in HA-MRSA isolates suggests clearly the circulation of clones of MRSA in the hospital setting that carry SCCmec types from the community as well.⁸ However, the distinction between CA-MRSA and HA-MRSA is becoming increasingly difficult, with migration of CA-MRSA being observed in health-care settings.^{1,2} This differentiation is important to understand their pathogenicity, antimicrobial resistance, molecular characteristics and clinical implications. Although




Figure 1. Heat map showing the distribution of SCCmec types among 217 MRSA clinical isolates, according to the year of collection.

Table 1. The primers and amplification conditions used to detect SCCmec types.

Primers	Sequences (5'-3')	Amplicon (bp)	PCR conditions
First reaction⁵			
mcABC1-F	ATTTTGAATCGCCATGAACA		Pre cycle 95°C 5 min
mcA-R	CGCATTGTCTTCGCCTTTTA	936	35 cycles: 95°C 30 s,
mcB-R	TTTGGGTTTCACTCGGATGT	676	61°C 45 s,
mcC1-R	GGGTTCAAGAATATGCACCAA	791	72°C 1 min
ccrB2-F	TCCAAAGTATGTTCCGGCAAC	563	Last cycle 72°C 10 min
ccrB2-R	TGCACTTCGTGAGTTGTTT		
ccrB4-F	TGCAACGGATGTTACAGT	394	
ccrB4-R	CGTTGTCTTTGGCCATTGTA		
Second reaction⁵			
mcC2-F	TCAGTTCATTGCTCACGATATG	411	
mcC2-R	ATGTCCCTCTGCATCAATGG		
ccrC-F	CCGGTCGTGTTTAGGCTAC	677	
ccrC-R	CACAYTTGACGCAATCTGCT		
ccrA1/3-F	GGMGAACAAGTCAAAAATGG		Pre cycle 95°C 5 min
ccrA1-R	TTCACAGACAAAACGAGATGC	519	35 cycles: 95°C 30 s,
ccA3-R	TTCGTTGCCGAAACAATAGG	326	57,5°C 45 s,
mecA-F	CCACCCTCAAACAGGTGAAT	796	72°C 1 min
mecA-R	CCCAATTTGTCTGCCAGTTT		Last cycle 72°C 10 min
Third reaction⁷			
IVa-F	GCCTTATCGAAGAAACCG	776	Pre cycle 94°C 5 min
IVa-R	CTACTCTTCTGAAAAGCGTCG		10 cycles: 94°C 45 s,
IVb-F	TCTGGAATTACTTCAGCTGC	493	63°C 45 s,
IVb-R	AAACAATATTGCTCTCCCTC		72°C 1.5 min
IVc-F	CCTGAATCTAAAGAGATACCCG	200	25 cycles: 94°C 45 s,
IVc-R	GGTTATTTTCATAGTGAATCGC		53°C 45 s,
IVd-F	CTCAAAATACGGACCCCAATACA	881	72°C 1.5 min
IVd-R	TGCTCCAGTAATTGCTAAAG		Last cycle 72°C 10 min

studies suggest a blurring of the line between CA-MRSA and HA-MRSA,¹⁰ continuous monitoring of CA- and HA-MRSA is necessary to understand the epidemiology and spread of these multiresistant pathogens.

ACKNOWLEDGMENTS

We are grateful the Federal University of Health Science of Porto Alegre (UFCSPA) for technical support in the development of this study.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

FINANCIAL SUPPORT

This study was supported by Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS).

REFERENCES

1. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol* 2019;17:203-18. doi: 10.1038/s41579-018-0147-4
2. Lakhundi S, Zhang K. Methicillin-Resistant *Staphylococcus aureus*: Molecular Characterization, Evolution, and Epidemiology. *Clin Microbiol Rev* 2018;31:e00020-18. doi: 10.1128/CMR.00020-18
3. Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant *Staphylococcus aureus*. *Nat Rev Dis Primers* 2018;4:18033. doi: 10.1038/nrdp.2018.33
4. Sowash MG, Uhlemann A-C. Community-associated methicillin-resistant *Staphylococcus aureus* case studies. *Methods Mol Biol* 2014;1085:25-69. doi: 10.1007/978-1-62703-664-1_2
5. Lawung R, Chuong LV, Cherdtrakulkiat R, et al. Revelation of staphylococcal cassette chromosome *mec* types in methicillin-resistant *Staphylococcus aureus* isolates from Thailand and Vietnam. *J Microbiol Methods* 2014;107:8-12. doi: 10.1016/j.mimet.2014.08.024
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. Document M100-S24. Wayne, PA: CLSI; 2019. p.55-69.
7. McClure-Warnier J-A, Conly JM, Zhang K. Multiplex PCR Assay for Typing of Staphylococcal Cassette Chromosome *mec* Types I to V in Methicillin-resistant *Staphylococcus aureus*. *J Vis Exp* 2013;79:e50779. doi: 10.3791/50779
8. Bashir Y, Bali N, Sharma S, et al. SCC_{mec} Type IV and V Methicillin-Resistant *Staphylococcus aureus* Intrusion in Healthcare Settings. *Am J Clin Microbiol Antimicrob* 2019;2:1032. doi: 10.1016/j.bjid.2019.04.005
9. Sit PS, The CSJ, Idris N, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia: Correlations between clinical, phenotypic, genotypic characteristics and mortality in a tertiary teaching hospital in Malaysia. *Infect Genet Evol* 2018;59:132-41. doi: 10.1016/j.mee-gid.2018.01.031
10. Bal AM, Coombs GW, Holden MTG, et al. Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated methicillin-resistant *Staphylococcus aureus*: Blurring of the traditional definitions. *J Glob Antimicrob Resist* 2016;6:95-101. doi: 10.1016/j.jgar.2016.04.004